Drug Repurposing of Voglibose, a Diabetes Medication for Skin Health

    February 2025 in “ Pharmaceuticals ”
    Hyeonmi Kim, Chang‐Gu Hyun
    Studysummary In this study, voglibose, commonly used for diabetes management, was found to reduce melanin synthesis and inhibit melanogenic signaling pathways in B16F10 melanoma cells, suggesting it could be repurposed for treating hyperpigmentation disorders with confirmed topical safety in human tests.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Tribuloside Acts on the PDE/cAMP/PKA Pathway to Enhance Melanogenesis, Melanocyte Dendricity and Melanosome Transport Journal of ethnopharmacology · 2023
    2. Application of Baricitinib in Dermatology Journal of inflammation research · 2022
    3. A Review of the Treatment of Male Pattern Hair Loss Expert Opinion on Pharmacotherapy · 2020